{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiagaidipcwc7kxfjr6brvz5g5rum2g6mv6ft3x7zrwr43sq7wui5m",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mgnb5vfll4w2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigdnpxklls7skskigy2duxuuccxuz5lrrf3akvibsqyyziuqz6uqi"
    },
    "mimeType": "image/jpeg",
    "size": 159615
  },
  "path": "/news/2026-03-biomimetic-platform-car-cell-therapy.html",
  "publishedAt": "2026-03-09T11:00:13.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T cells to target specific antigens on leukemia cells, with the goal of identifying and eliminating them. However, clinical data show that more than 50% of patients eventually relapse after CAR T treatment. One major reason is that leukemia cells can reduce or lose expression of the targeted antigen under therapeutic pressure. When this occurs, CAR T cells can no longer effectively recognize and eliminate leukemia cells.",
  "title": "Biomimetic platform developed to enhance CAR T cell therapy against leukemia"
}